Loading…
Loading…
can you give us some help on the proportion of sales from Skyrizi in IBD now or percentage of number of scripts getting IBD induction
did the strong performance include any notable onetime contributions, inventory build or pull forward effects
did you see any notable difference in trends in stocking or gross-to-net patterns across the portfolio ahead of the changes in Part D
Do you see increasing commercial competition from Leqvio in general? And going forward, there is going to be some late-stage data oral PCSK9 this year.
how you thinking about the weight loss for orfo in the ATTAIN obesity studies?
Could that be a reasonable comp for the obesity studies in '26, unlike what you flagged with ortho and diabetes?
does this One Big Beautiful Bill update effectively shift KEYTRUDA's IRA selection from 2028 to 2029
can you perhaps talk about your manufacturing footprint from China, Mexico and Canada
how are you sizing the '25 to '26 U.S. fall season versus last year?
Does that imply you think something is going to happen this year? And if so, what's your broad assumption so we can kind of quantify that hit
How much of that can come out in 2025? And how should we think about the step up of cost for the rest of the year
How much is that macro environment impacting your decision in the timing of BD given the volatility and unknowns?
just wondering how you're going to position this, and how quick could you penetrate this population if approved?
do you have any insight if there's going to be a discussion from ACIP on revaccination or cohort expansion this year?